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Most neuromuscular diseases that are genetically deter-
mined are expressed already in childhood, but some of 
them show the real clinical picture and are determined in 
adulthood. If the latter is the case, consultation on further 
genetic information may be difﬁ cult or impossible5.
Anterior Horn Cell Disease of Spinal Cord and 
Motor Nuclei Cranial Nerves
These are the progressive degenerating motor neuron 
diseases of the spinal cord, brainstem and cortical motor 
neurone. The frequency is 1–2 patients per 100,000 per-
sons2,6.
Spinal muscular atrophies
Spinal Muscular Atrophies (SMA) are caused by muta-
tions in the SMN1 gene localized on Chromosome 5q11. 
SMN gene is necessary for the creation of small nuclear 
ribonucleins which are involved in the process of the cre-
ation of mRNA. SMA is the second most frequent autoso-
Disorder in the function and structure of the motor 
unit is called neuromuscular disease1. Getting to know the 
molecular structure of the genome as a hereditary poten-
tial located in every cell in the form of the human DNA 
has been the subject of research for many years. Genomic 
revolution, which started with the human genome project 
and the sequencing of the human genome, is now directed 
toward a personal genome and more personalized medi-
cine2. The question is how to apply the above – features, 
advantages and limitations of this revolution. The genome 
contains the data of life in the form of the biological code. 
It should also be recognized that the DNA is a living or-
ganism that changes due to lifestyle, environmental fac-
tors, by changing and the regulation of the genes. Genes 
carry the codes for proteins of our organism, so qualita-
tively and quantitatively altered proteins lead to diseases2.
If someone is predisposed to a health risk they and 
their doctor should know it, and start the medical treat-
ment in advance, and in that way affect the creation of 
offspring3. Naturally, this raises signiﬁ cant ethical issues 
and laws must have strict guidelines in order not to abuse 
but take good advantage of this conﬁ dential material4. 
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A B S T R A C T
Following the completion of the Human Genome Project, a lot of progress has been made in understanding the ge-
netic basis of motor neuron diseases (MNDs) and neuropathies. Spinal Muscular Atrophies (SMA) are caused by mutations 
in the SMN1 gene localized on Chromosome 5q11. Amyotrophic Lateral Sclerosis (ALS) has been found to have at least 
18 different types, many of them associated to different genetic loci (e.g. SOD1, ALS2, SETX, FUS, VAPB, ANG, TARDBP 
and others), but many of the forms have still not been associated with a particular gene. Sensomotoric hereditary neu-
ropathies (Charcot-Marie-Tooth) are a large heterogeneous group of various hereditary neuropathies, which have also 
been associated with a wide spectrum of genetic mutations, such as PMP22, LITAF, EGR2, P0 protein, KIF1B, MFN2, 
RAB7 and others. It is also apparent that more genes are being implicated, mutations discovered, and phenotypes recog-
nised and broadened. Therefore, a lot of continuing, additional research effort will be required in the coming years to il-
luminate pathogenic mechanisms that underlie motor neuron diseases and neuropathies and that could lead to new and 
improved treatments.
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mal recessive disease with the frequency of 1 in 10,000 
live newborns; the frequency carrier is (1/40–1/603)2,6. 
SMA region is very unstable due to frequent deletions and 
gene conversion, and the number of gene copies can vary 
from 0–4 per chromosome. For the majority of Caucasian 
population the most frequent number of copies of genes is 
2. SMN1 gene determines the status of SMA carriers as 
well as SMA patients. In 95% of the cases of SMA the 
patients are homozygotes for the lack of axon 7 on SMN1 
gene, while the 3.6% are complex heterozygotes with a 
point mutation on the second allele1,2,6.
There is an opinion that the number of SMN2 gene 
copies and gene Naipi can determine the severity of the 
disease. SMA carriers are in most cases heterozygotes, 
with no signs of disease, with one copy of axon 7 of SMN1 
gene and 0 or more copies of axon 8 of SMN1 gene. SMN2 
without mRNA in 80% of the cases are pre-Mrna attached 
in the SMN without exon 7. SMN without exon 7 is un-
stable and it quickly disintegrates7.
Amyotrophic lateral sclerosis
Until now, a number of genetic mutations have been 
found to be associated with different types of ALS1,2,6,7. 
(Table 1)
Acquired motor neuron diseases occur due to the 
disorder on chromosome 21 which converts superoxide (O2) 
into hydrogen (H2O2). It is a defect of superoxide dismutase, 
which leads to a defect of converting Cu/Zn, the increase 
in the number of free radicals that could lead to oxidative 
stress7,8. The glutamate is not ejected from the synapses 
ﬁ eld. The same changes can (more rarely) be caused by the 
disorder of chromosome 5q. It is inherited as an X-recessive 
forms, or X – dominant forms7,8.
Distal, scapuloperoneal, facioscapular amiotrophy
Distal, scapuloperoneal, facioscapular amiotrophy is 
characterized by a speciﬁ c abstraction of muscle atrophies 
and gradual development of deformities, slow disease pro-
gression, shutting down of myotic reﬂ exes and atony. Ac-
cording to the characteristic EMNG ﬁ ndings, the differ-
ential diagnosis is made according to dystrophies. All are 
caused by a genetic mutation in the SMN1 gene localized 
on Chromosome 5q11, with a different penetration of genes 
(fewer repetitions of nucleotides)1,2,8,9.
Parents who have a child affected by SMA are recom-
mended to perform a prenatal diagnosis for every follow-
ing pregnancy because there is a 25% risk to have a child 
affected by this disease. This way, we can determine the 
point mutations. In 4% of patients with 2 copies of SMN1 
exon 7 is the carrier, as both copies are on the same chro-
mosome, which can also be determined by this method8,9.
Sensomotoric hereditary neuropathies
Sensomotoric hereditary neuropathies (Charcot-Marie-
Tooth) are a large heterogeneous group of various heredi-
tary neuropathies1,10.
As this is a group of heterogenic diseases, the inheri-
tance of HMSN can be different9,10. Type 1 (1A) in which 
demyelination is created as well as creation of bulbs, is 
inherited autosomal dominant recessively. These patients 
TABLE 1
GENETIC MUTATIONS ASSOCIATED WITH DIFFERENT TYPES OF ALS
Type OMIM Gene Locus Clinical codes
ALS1 105400 SOD1 21q22.1 Most frequent forms of ALS
ALS2 205100 ALS2 2q33.1
ALS3 606640 ? 18q21
ALS4 602433 SETX 9q34.13
ALS5 602099 ? 15q15.1–q21.1 Juvenile start
ALS6 608030 FUS 16p11.2
ALS7 608031 ? 20p13
ALS8 608627 VAPB 20q13.3
ALS9 611895 ANG 14q11.2
ALS10 612069 TARDBP 1p36.2
ALS11 612577 Fig4 6q21
ALS12 613435 OPTN 10p13
ALS13 183090 ATXN2 12q24.12
ALS14 613954 VCP 9p13.3 Rare, described in only one family described in one family
ALS15 300857 UBQLN2 Xp11.23–p11.1
ALS16 614373 SIGMAR1 9p13.3 Juvenile start, very rare, described in only one family
ALS17 614696 CHMP2B 3p11 Very rare, described only in a few patients
ALS18 614808 PFN1 17p13.3 Very rare, described only in a few Chinese families
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TABLE 2
A SUMMARY OF KNOWLEDGE ON GENETICS AND THE INHERITANCE OF HEREDITARY NEUROPATHIES
Gene Inheritance Locus
HMSN1-CMT1
CMT1A: PMP-22 Dominant/sporadic 17p11
CMT1B: P0 protein Dominant LQ22
CMT1C: LITAF Dominant 16pl3
CMT1D: EGR2 Dominant 10q21
CMT1E: P0 protein Dominant LQ22
CMT1F: Neuroﬁ lament light chain Dominant/sporadic 8p21
HMSN2-CMT2
CMT2A1: KIF1B Dominant lp36
CMT2A2: MFN2 Dominant lp36
CMT2B: RAB7 Dominant 3ql3–q22
CMT2C: TRPV4 Dominant 12q23–Q24
CMT2D: Gars Dominant 7pl5
CMT2E: Neuroﬁ lament light chain Dominant 8p21
CMT2F: HSPB1 Dominant/recessive 7q11–q21
CMT2G: Dominant 12ql2
CMT2I: PO Dominant LQ22
CMT2J: PO Dominant LQ22
CMT2L: HSPB Dominant 12q24
AR-CMT2A Lam in A/C Recessive lq21.2
AR-CMT2E Med25 Recessive 19ql3.3
CMT2K: GDAP1 Dominant/recessive 8q21
HMSN3DSN/CHN
DSNA PMP-22 Dominant/recessive 17p11–2
DSNB MP2 Dominant/recessive LQ22
DSNC EGRP2 Dominant 10q21/EGR2
DSND Dominant Sq23–24
DSN PRX Recessive 19ql3.1–13.2
DSN GDAP1 Recessive 8ql3–21.1
Congenital hypomyelination
CHA 22 PMO Dominant 17p11.2
CHB MP2 Dominant LQ22
CHC EGRP2 Dominant/recessive 10q21
HMSN4-CMT4
CMT4A: GDAP1 Recessive 8q21
CMT4B1: MTMR2 Recessive 11q23
CMT4B2: SBF2 Recessive 11p15
CMT4C: SH3TC2 (KLAA1985) Recessive 5q32
CMT4D: NDRG1 Recessive 8q24
CMT4E: EGR2 Dominant/recessive 10q21
CMT4F: Periaxin Recessive 19ql3
CMT4H: FGD4 Recessive 12ql2
CMT4J Fig4 Recessive 6q21
HSMN5
Silver syndrome Seipin/BSCL2 Dominant 11ql3
Troyer syndrome SPG20 Recessive 13ql2.3
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revealed the duplication of peripheral myelin protein, lo-
cated on the gene 22 (PMP22) on chromosome 17q11.2. 
Type 2 or axonal form (according to EMNG fi ndings) is 
inherited autosomal dominant or recessively (the gene re-
sponsible for this form is gene1 and gene 22). CMT-3, 4 
CMT, CMT X are inherited recessively and the gene re-
sponsible is gene one, but sometimes the changes have 
been found in the gene PMP22 as well1,10. It was found that 
a mutation in exon 21 and exon 22 on the gene SCN9A are 
responsible for the loss of sensitivity and the autonomic 
nervous system disorders1,2,8–10.
Hereditary neuralgic amiotrophy
Hereditary neuralgic amiotrophy is caused by muta-
tions on the gene SEPT9 (17q25). The same is idiopathic 
brachial neuralgic amiotrophy (plexopathy)-Personage-
Turner syndrome1.
Compressive neuropathies
Hereditary compression neuropathies with a penchant 
paralysis can be found in 2 to 5 people per 100,000 inhab-
itants. The mutation on the PMP 22 gene causes neuropa-
thies with a penchant on the pressure palsy. The loss of 
one copy of on the PMP 22 gene or its alteration leads to 
instability of the myelin sheath. The disease is inherited 
autosomal dominantly10.
Discussion
Genetic background and pathogenesis of motor neuron 
diseases (MNDs) have been increasingly elucidated over 
recent years2. Phenotypic manifestations of MNDs include 
spinal muscular atrophies (SMA), familial or sporadic 
amyotrophic lateral sclerosis (fALS, sALS), bulbospinal 
muscular atrophy (BSMA), and unclassifi ed MNDs2. An 
increasing number of mutated genes is recently recognised 
in fALS, but also sALS patients. Genes mutated in sALS 
include C9orf72, SOD1, TARDBP, FUS, UBQL2, 
SQSTM1, DCTN1, and UNC13A. Juvenile fALS is most 
frequently caused by mutations in ALS2, SETX, spatac-
sin, or Sigmar1, and adult fALS by mutations in C9orf72, 
SOD1, TARDBP, and FUS. There are differences between 
geographic regions, mutations and genes that affect the 
onset, phenotype, progression, and outcome of ALS2.
Renton et al.11 also reviewed genes implicated in the 
pathogenesis of motor neuron degeneration, namely ALS, 
SOD1, TARDBP, FUS, OPTN, VCP, UBQLN2, C9ORF72 
and PFN1. They also outlined next-generation sequencing 
approaches to identify de novo mutations, the genetic con-
vergence of familial and sporadic ALS, and how each new 
genetic discovery is broadening the phenotype associated 
with the clinical entity we know as ALS11.
Recently, Scotton et al.3 recognised that clinical trials 
of new therapies are diffi cult due to lack of reliable and 
monitorable clinical outcome measures. They proposed 
biomarkers as a way to speed up research, providing an 
insight into the pathophysiological mechanisms behind 
such diseases3. Biomarkers, which could include genetic 
profi ling of each patient, may provide invaluable tools for 
monitoring the progression, prognosis and individualised 
treatment3. They summarized the types, applications, 
characteristics and best strategies for biomarker discov-
ery3.
Conclusion
We can conclude that a considerable progress has been 
made over the past several year in the clarifi cation and 
understanding of the etiology and pathogenesis of MNDs, 
particularly due to research technologies that were made 
available after the human genome was sequenced more 
than a decade ago2. However, it is also apparent that more 
genes are being implicated, mutations discovered, and 
phenotypes recognised and broadened. Therefore, a lot of 
additional effort will be required in the coming years to 
illuminate pathogenic mechanisms that underlie motor 
neuron diseases and neuropathies and that could lead to 
new and improved treatments2,11.
Fig. 1. Charcot-Marie-Tooth disease (hereditary sensory 
neuropathies Type A).
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GEN ETSKE OSNOVE BOLESTI MOTONEURONA I NEUROPATIJE
S A Ž E T A K
Nakon završetka Projekta ljudskog genoma, dosta je napretka postignuto u razumijevanju genetske osnove bolesti 
motoneurona (MNDS) i neuropatija. Spinalne mišićne atroﬁ je (SMA) su uzrokovane mutacijama u genu SMN1 loka-
liziranih na kromosomu 5q11. Za amiotroﬁ čne lateralne skleroze (ALS) utvrđeno je da imaju najmanje 18 različitih 
vrsta, a mnoge od njih su povezane za različite genetske lokuse (npr SOD1, ALS2, SETX, FUS, VAPB, Ang, TARDBP 
i drugi), ali za mnoge od oblika još nije nađena povezanost sa određenim genom. Senzomotorne nasljedne neuropatije 
(Charcot-Marie-Tooth) su velika heterogena skupina raznih nasljednih neuropatija, koje su povezane sa širokim spektrom 
genetskih mutacija, kao što su PMP22, LITAF, EGR2, P0 proteina, KIF1B, MFN2, RAB7 i drugi. Također je jasno da 
se sve više gena implicira, mutacija otkriva i fenotipa tih bolesti prepoznaje i širi. Dakle, puno dodatnih istraživanja i 
truda će biti potrebno u narednim godinama za osvjetljavanje patogenetskih mehanizama na kojima se zasnivaju boles-
ti motoneurona i neuropatije i koji bi mogli dovesti do novih i poboljšanih načina liječenja.
